BCG: Medtech's AI Payoff Comes From Connecting the Commercial Engine
BCG’s latest medtech benchmark puts a number on what connected AI is worth in commercial operations: about two percentage points of EBITDA, roughly three times the capital expenditure required. The figure comes from BCG’s fourth global medtech commercial benchmarking study in 15 years, built on input from more than 10,000 employees and a benchmark of 150 medtech businesses.
The gap it exposes is capability, not appetite. Executives still rate their newer commercial capabilities as only basic to intermediate. Yet the companies that developed such a commercial model delivered annual total shareholder return eight percentage points above the MSCI Health Care Equipment and Supplies Index.
BCG names five moves: continuous prioritization and dynamic targeting, personalized engagement, AI-augmented and autonomous sales, data-driven pricing, and agentic AI for customer experience. The evidence behind them is specific. A real-time 360-degree buyer view can often double the number of relevant leads and lift conversion by 30% to 50%. A global diagnostics leader that combined interactions, purchase history, installed-base and CRM data into one next-best-action platform doubled the likelihood that customers acted on a recommendation. AI pricing recommendations and negotiation simulators raised price adoption by 1.5 percentage points in the annual adjustment.
Read those results as a statement about plumbing. The 360-degree view and the diagnostics platform both depend on unified data feeding one decision layer, not a standalone tool bolted onto a rep’s workflow. Any company selling through complex, relationship-heavy channels should ask the same question before buying anything: which data has to be connected before the AI can act on it?
BCG is also explicit that AI does not replace reps and needs governance and humans in the loop. That is the part worth wielding as a rule. Ship the connected data layer first, keep a person accountable for each decision, and measure the EBITDA outcome rather than the pilot count.